Evidence map›Paper›PMID 35237063›Full record

ArticleJournal of inflammation research2022

Serum Levels of IL-1 RA Increase with Obesity and Type 2 Diabetes in Relation to Adipose Tissue Dysfunction and are Reduced After Bariatric Surgery in Parallel to Adiposity.

Gema Frühbeck, Victoria Catalán, Beatriz Ramírez, Víctor Valentí, Sara Becerril, Amaia Rodríguez, Rafael Moncada, Jorge Baixauli, Camilo Silva, Javier Escalada and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of inflammation research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Dark Sweet Cherry (Nutrients · 2023
    Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Relevance of body composition in phenotyping the obesities.Reviews in endocrine & metabolic disorders · 2023
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Gema FrühbeckMetabolic Research Laboratory, Clínica Universidad de Navarra, Pamplona, Spain.ORCID 0000-0002-8305-7154
Victoria CatalánMetabolic Research Laboratory, Clínica Universidad de Navarra, Pamplona, Spain.ORCID 0000-0002-7513-7509
Beatriz RamírezMetabolic Research Laboratory, Clínica Universidad de Navarra, Pamplona, Spain.
Víctor ValentíCentro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Pamplona, Spain.
Sara BecerrilMetabolic Research Laboratory, Clínica Universidad de Navarra, Pamplona, Spain.
Amaia RodríguezMetabolic Research Laboratory, Clínica Universidad de Navarra, Pamplona, Spain.ORCID 0000-0002-2180-461X
Rafael MoncadaCentro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Pamplona, Spain.
Jorge BaixauliDepartment of Surgery, Clínica Universidad de Navarra, Pamplona, Spain.ORCID 0000-0002-0667-7827
Camilo SilvaCentro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Pamplona, Spain.
Javier EscaladaCentro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Pamplona, Spain.
Javier Gómez-AmbrosiMetabolic Research Laboratory, Clínica Universidad de Navarra, Pamplona, Spain.ORCID 0000-0001-5601-1604
Instituto de Salud Carlos III · ESClinica Universidad de Navarra · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExcess adiposity leads to a dysfunctional adipose tissue that contributes to the development of obesity-associated comorbidities such as type 2 diabetes (T2D). Interleukin-1 receptor antagonist (IL-1RA) is a naturally occurring antagonist of the IL-1 receptor with anti-inflammatory properties. The aim of the present study was to compare the circulating concentrations of IL-1RA and its mRNA expression in visceral adipose tissue (VAT) in subjects with normal weight (NW), obesity with normoglycemia (OB-NG), or obesity with impaired glucose tolerance or T2D (OB-IGT&T2D) and to analyze the effect of changes in body fat percentage (BF%) on IL-1RA levels.

methodsSerum concentrations of IL-1RA were measured in 156 volunteers. Expression of

resultsSerum levels of IL-1RA were significantly increased in individuals with obesity, being further increased in the OB-IGT&T2D group (NW 440 ± 316, OB-NG 899 ± 562, OB-IGT&T2D 1265 ± 739 pg/mL;

conclusionSerum IL-1RA concentrations are increased in patients with obesity being further elevated in obesity-associated IGT and T2D in association with markers of adipose tissue dysfunction. The mRNA expression of

Indexed as

adipokinesadipose tissueIL-1RAinflammationobesitytype 2 diabetes

Identifiers

PMID35237063
PMCPMC8884708
OpenAlexW4213417788

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.